<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Lecanemab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Lecanemab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Lecanemab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="140478" href="/d/html/140478.html" rel="external">see "Lecanemab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F58495963"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Amyloid-related imaging abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Monoclonal antibodies directed against aggregated forms of beta amyloid, including lecanemab, can cause amyloid-related imaging abnormalities (ARIA), characterized as ARIA with edema (ARIA-E) and ARIA with hemosiderin deposition (ARIA-H). Incidence and timing of ARIA vary among treatments. ARIA usually occurs early in treatment and is usually asymptomatic, although serious and life-threatening events rarely can occur. Serious intracerebral hemorrhages, some of which have been fatal, have been observed in patients treated with this class of medications.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>ApoE ε4 homozygotes:</b> Patients who are apolipoprotein E ε4 (ApoE ε4) homozygotes (approximately 15% of Alzheimer disease patients) treated with this class of medications, including lecanemab, have a higher incidence of ARIA, including symptomatic, serious, and severe radiographic ARIA, compared to heterozygotes and noncarriers. Testing for ApoE ε4 status should be performed prior to initiation of treatment to inform the risk of developing ARIA. Prior to testing, prescribers should discuss with patients the risk of ARIA across genotypes and the implications of genetic testing results. Prescribers should inform patients that if genotype testing is not performed, they can still be treated with lecanemab; however, it cannot be determined if they are ApoE ε4 homozygotes and at higher risk for ARIA.</p>
<p style="text-indent:-2em;margin-left:2em;">Consider the benefit of lecanemab for the treatment of Alzheimer disease and potential risk of serious adverse events associated with ARIA when deciding to initiate treatment with lecanemab.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F57836136"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Leqembi</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F57641285"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anti-Amyloid Monoclonal Antibody;</li>
<li>
                        Immune Globulin;</li>
<li>
                        Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F57817561"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Confirm the presence of amyloid beta pathology prior to treatment initiation. Testing for apolipoprotein E ε4 (ApoE ε4) status prior to treatment initiation is recommended.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a3041b3d-3f11-47c1-815e-01b475c1f691">Alzheimer disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Alzheimer disease: IV:</b> Dosing based on actual body weight: 10 mg/kg once every 2 weeks.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F57817563"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, lecanemab is not expected to undergo renal elimination.</p></div>
<div class="block doha drugH1Div" id="F57817564"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling; however, lecanemab is not expected to undergo hepatic metabolism.</p></div>
<div class="block dot drugH1Div" id="F57817566"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Amyloid-related imaging abnormalities (ARIA), symptoms:</b> Perform clinical evaluation, including MRI if indicated.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Amyloid-related imaging abnormalities – edema (ARIA-E): </b>See table below:</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>ARIA-E Associated With Lecanemab</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Severity of clinical symptoms<sup>a</sup></b></p></th>
<th align="left" colspan="2">
<p style="text-indent:0em;">
<b>ARIA-E severity on MRI</b></p></th></tr>
<tr>
<th align="left"></th>
<th align="left">
<p style="text-indent:0em;">
<b>Mild</b></p></th>
<th align="left">
<p style="text-indent:0em;">
<b>Moderate or severe</b></p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="3">
<p style="text-indent:0em;">
<sup>a</sup> For patients experiencing symptoms associated with ARIA, perform clinical evaluation, including MRI if indicated.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Asymptomatic</b></p></td>
<td align="left">
<p style="text-indent:0em;">Continue current lecanemab dosing.</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold lecanemab until MRI shows radiographic resolution. Consider follow-up MRI to assess for resolution (eg, 2 to 4 months following initial ARIA-E identification); resume dosing based on clinical judgment.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Mild<sup>a</sup></b> (eg, discomfort but no disruption of normal daily activity)</p></td>
<td align="left">
<p style="text-indent:0em;">Continue lecanemab dosing based on clinical judgment.</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold lecanemab until MRI shows radiographic resolution and symptoms resolve. Consider follow-up MRI to assess for resolution (eg, 2 to 4 months following initial ARIA-E identification); resume dosing based on clinical judgment.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Moderate or severe<sup>a</sup></b> (eg, symptoms ranging from discomfort that impacts normal daily activity to incapacitation and inability to perform normal daily activity or work)</p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">Withhold lecanemab until MRI shows radiographic resolution and symptoms resolve. Consider follow up MRI to assess for resolution (eg, 2 to 4 months following initial ARIA-E identification); resume dosing based on clinical judgment.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">
<b>Amyloid-related imaging abnormalities – hemosiderin (ARIA-H):</b> See table below:</p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<caption style="text-align:left;">
<b>ARIA-H Associated With Lecanemab</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead valign="middle">
<tr>
<th align="left">
<p style="text-indent:0em;">
<b>Severity of clinical symptoms<sup>a</sup></b></p></th>
<th align="left" colspan="3">
<p style="text-indent:0em;">ARIA-H Severity on MRI</p></th></tr>
<tr>
<th align="left"></th>
<th align="left">
<p style="text-indent:0em;">
<b>Mild</b></p></th>
<th align="left">
<p style="text-indent:0em;">Moderate</p></th>
<th align="left">
<p style="text-indent:0em;">Severe</p></th></tr></thead>
<tfoot valign="top">
<tr>
<td align="left" colspan="4">
<p style="text-indent:0em;">
<sup>a</sup> For patients experiencing symptoms associated with ARIA, perform clinical evaluation, including MRI if indicated.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Asymptomatic</b></p></td>
<td align="left">
<p style="text-indent:0em;">Continue current lecanemab dosing.</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold lecanemab until MRI shows radiographic stabilization. Consider follow up MRI to assess for resolution (eg, 2 to 4 months following initial ARIA-H identification); resume dosing based on clinical judgment.</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold lecanemab until MRI shows radiographic stabilization. Use clinical judgment to determine whether to continue treatment or permanently discontinue lecanemab.</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;">
<b>Symptomatic<sup>a</sup></b></p></td>
<td align="left" colspan="2">
<p style="text-indent:0em;">Withhold lecanemab until MRI shows radiographic stabilization and symptoms resolve. Consider follow up MRI to assess for resolution (eg, 2 to 4 months following initial ARIA-H identification); resume dosing based on clinical judgment.</p></td>
<td align="left">
<p style="text-indent:0em;">Withhold lecanemab until MRI shows radiographic stabilization and symptoms resolve. Use clinical judgment to determine whether to continue treatment or permanently discontinue lecanemab.</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Intracerebral hemorrhage &gt;1 cm in diameter:</b> Withhold lecanemab until MRI shows radiographic stabilization and symptoms (if present) resolve. Use clinical judgment to determine whether to continue treatment or permanently discontinue lecanemab.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypersensitivity reaction signs/symptoms (eg, angioedema, bronchospasm, anaphylaxis</b>
<b>)</b>: Promptly discontinue infusion at first sign/symptom of hypersensitivity and initiate appropriate treatment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion reaction signs/symptoms (eg, fever, flu-like symptoms, nausea, vomiting, BP changes): </b>Consider reducing rate of administration, discontinuing the infusion, and/or initiating supportive therapy as clinically appropriate. Consider premedication with antihistamines, acetaminophen, nonsteroidal anti-inflammatory drugs, or corticosteroids prior to future infusions.</p></div>
<div class="block doe drugH1Div" id="F57817562"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block arsc drugH1Div" id="F57978136"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Amyloid-related imaging abnormalities</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Amyloid-related imaging abnormalities (ARIA), including ARIA consistent with vasogenic edema and/or sulcal effusions (ARIA-E) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35099507','lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35099507','lexi-content-ref-21784348'])">Ref</a></span>) and ARIA with hemosiderin deposition (ARIA-H) characterized by superficial siderosis, microhemorrhages, and macrohemorrhages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35099507','lexi-content-ref-36949897','lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35099507','lexi-content-ref-36949897','lexi-content-ref-21784348'])">Ref</a></span>) have been reported with lecanemab therapy. Patients may develop ARIA-H with concomitant ARIA-E. In patients who developed ARIA during lecanemab clinical trials, most cases were asymptomatic with mild to moderate radiographic severity; however, serious and/or fatal symptoms have been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36949897','lexi-content-ref-36449413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36949897','lexi-content-ref-36449413'])">Ref</a></span>). Recurrent episodes of ARIA-E have also been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36949897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36949897'])">Ref</a></span>). Clinical symptoms suggesting ARIA may include abnormal gait, confusion, dizziness, focal neurologic deficits, headache, nausea, visual disturbance, and seizures. Resolution of ARIA (-E and/or -H) occurred within 4 months in the majority of cases in clinical trials (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36449413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36449413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; speculated that increased clearance of amyloid from parenchymal plaques into perivascular space may result in excess fluid shifts. This movement of amyloid into cerebral vessel walls may also increase vascular friability and permeability, thus impairing vessel wall integrity to permit small amounts of blood passage. Increased vascular permeability at which both fluid and red blood cells cross the vessel wall may suggest a common pathophysiologic mechanism for both ARIA-E and ARIA-H (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23578674','lexi-content-ref-35099507','lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23578674','lexi-content-ref-35099507','lexi-content-ref-21784348'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">ARIA-E: Dose-related; related to the pharmacologic action. Increased cerebrovascular permeability due to antibody binding to deposited amyloid-beta results in an increase in extracellular fluid volume and vasogenic edema (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31827267','lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31827267','lexi-content-ref-21784348'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">ARIA-H: Dose-related; related to the pharmacologic action. Leakage of blood from a vessel into adjacent tissue parenchyma or subarachnoid space/periadventitial compartments leaves residual deposits of iron in the form of hemosiderin, resulting in superficial siderosis and/or radiographic evidence of hemorrhage (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21784348'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; ARIA may occur at any time during treatment, but most events occur within the first 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-36449413']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-36449413'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">ARIA-E:</p>
<p style="text-indent:-2em;margin-left:8em;">• Apolipoprotein E ε4 carriers; specifically ApoE ε4 homozygotes</p>
<p style="text-indent:-2em;margin-left:8em;">• Dose; risk increases with higher doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35099507','lexi-content-ref-31827267']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35099507','lexi-content-ref-31827267'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">ARIA-H: Microhemorrhages:</p>
<p style="text-indent:-2em;margin-left:8em;">• Apolipoprotein E ε4 carriers; specifically ApoE ε4 homozygotes</p>
<p style="text-indent:-2em;margin-left:8em;">• Increasing age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21784348'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Older adults with cardiovascular risk factors and/or evidence of prior cerebrovascular event (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21784348']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21784348'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Concomitant risk factors for intracerebral hemorrhages (prior cerebral hemorrhage &gt;1 cm, &gt;4 microhemorrhages, superficial siderosis, vasogenic edema, aneurysm, vascular malformation)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F57645374"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemosiderosis (ARIA-H, including microhemorrhage and superficial siderosis: 6% to 17%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Infusion-related reaction (20% to 26%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Brain edema (ARIA-E, including sulcal effusion: 10% to 13%), headache (11% to 14%)<span class="lexi-table-link-container"> (<a aria-label="Headache table link" class="lexi-table-link" data-table-id="lexi-content-headache" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-headache')">table 1</a>)</span><span class="table-link" style="display:none;">Headache</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Headache" frame="border" id="lexi-content-headache" rules="all">
<caption style="text-align:center;">
<b>Lecanemab: Adverse Reaction: Headache</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Lecanemab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Lecanemab)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">14%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/kg every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">161</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">245</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">10 mg/kg every 2 weeks</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">898</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">897</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (8%), nausea and vomiting (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Lymphocytopenia (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (9%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%: Nervous system: Cerebral hemorrhage</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Increased neutrophils</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (including anaphylaxis and angioedema)</p></div>
<div class="block coi drugH1Div" id="F57641273"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Serious hypersensitivity (eg, anaphylaxis, angioedema) to lecanemab or any component of the formulation.</p></div>
<div class="block war drugH1Div" id="F57817551"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Concerns related to adverse effects:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reaction: Lecanemab may cause infusion reactions; symptoms include fever, flu-like symptoms (chills, generalized aches, shakiness, joint pain), nausea, vomiting, hypotension, hypertension, and oxygen desaturation. The highest incidence of infusion reactions occurs with the first infusion.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Dosage form specific issues:</b></i></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block foc drugH1Div" id="F57836137"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Leqembi: Lecanemab-irmb 200 mg/2 mL (2 mL); Lecanemab-irmb 500 mg/5 mL (5 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F57836135"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F57892223"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Leqembi Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg/2 mL (per mL): $152.89</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg/5 mL (per mL): $152.88</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F57817574"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>IV:</b> Dilution required prior to administration. Administer by IV infusion over 1 hour through an IV line containing a terminal low-protein binding 0.2 micron in-line filter. Flush IV line following infusion.</p></div>
<div class="block meg drugH1Div" id="F57840741"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Leqembi: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F761269s001lbl.pdf%23page%3D21&amp;token=iqRdRgPwJzyJywRAJexi0c9TTP9YmB1B00PhvuksEF7rm8%2F17fPXzper%2FSMtd%2FD8Z825RYT1giYvX0xc88XKtatwM9BgsV4uHO4E2MJ38Nn0%2B17Rp6RKggmGGptYZOOn&amp;TOPIC_ID=140477" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761269s001lbl.pdf#page=21</a></p></div>
<div class="block use drugH1Div" id="F57641272"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Alzheimer disease:</b> Treatment of Alzheimer disease; to be initiated in patients with mild cognitive impairment or mild dementia stage of disease.</p></div>
<div class="block cyt drugH1Div" id="F57810996"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F57810993"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): Lecanemab may enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Lecanemab may enhance the adverse/toxic effect of Anticoagulants. Specifically, the risk of hemorrhage may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Lecanemab may enhance the adverse/toxic effect of Thrombolytic Agents. Specifically, the risk of hemorrhage may be increased. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F57817531"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Animal reproduction studies have not been conducted.</p>
<p style="text-indent:0em;margin-top:2em;">Lecanemab is a humanized monoclonal antibody (IgG<sub>1</sub>). Human IgG crosses the placenta. Fetal exposure is dependent upon the IgG subclass, maternal serum concentrations, placental integrity, newborn birth weight, and GA, generally increasing as pregnancy progresses. The lowest exposure would be expected during the period of organogenesis and the highest during the third trimester (Clements 2020; Palmeira 2012; Pentsuk 2009).</p></div>
<div class="block brc drugH1Div" id="F57817532"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if lecanemab is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab is a humanized monoclonal antibody (IgG<sub>1</sub>). Human IgG is present in breast milk; concentrations are dependent upon IgG subclass and postpartum age (Anderson 2021).</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and the benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F57817577"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">PET or lumbar puncture to confirm presence of amyloid beta pathology (prior to initiation) (van Dyck 2023); apolipoprotein E ε4 (ApoE ε4) status testing (prior to initiation); brain MRI (prior to initiation [within 1 year]; prior to 5th, 7th, 14th infusions; periodically as appropriate in the setting of amyloid-related imaging abnormalities (ARIA) [eg, 2 to 4 months following identification of ARIA]); monitor closely for clinical and MRI changes; monitor for symptoms suggestive of ARIA (eg, headache, altered mental status, visual changes, dizziness, nausea, gait difficulty, focal neurologic deficits, seizure).</p></div>
<div class="block pha drugH1Div" id="F57817556"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Lecanemab is a humanized monoclonal antibody directed against aggregated soluble and insoluble forms of amyloid beta. Lecanemab reduces amyloid beta plaques, the accumulation of which is a defining pathophysiological feature of Alzheimer disease.</p></div>
<div class="block phk drugH1Div" id="F57817557"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 3.24 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Degradation by proteolytic enzymes.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 5 to 7 days.</p></div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lecanemab-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33956488">
<a name="33956488"></a>Anderson PO. Monoclonal antibodies during breastfeeding. <i>Breastfeed Med</i>. 2021;16(8):591-593. doi:10.1089/bfm.2021.0110<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lecanemab-drug-information/abstract-text/33956488/pubmed" id="33956488" target="_blank">33956488</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23578674">
<a name="23578674"></a>Barakos J, Sperling R, Salloway S, et al. MR imaging features of amyloid-related imaging abnormalities. <i>AJNR Am J Neuroradiol</i>. 2013;34(10):1958-1965. doi:10.3174/ajnr.A3500<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lecanemab-drug-information/abstract-text/23578674/pubmed" id="23578674" target="_blank">23578674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lecanemab-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33013843">
<a name="33013843"></a>Clements T, Rice TF, Vamvakas G, et al. Update on transplacental transfer of IgG subclasses: impact of maternal and fetal factors. <i>Front Immunol</i>. 2020;11:1920. doi:10.3389/fimmu.2020.01920<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lecanemab-drug-information/abstract-text/33013843/pubmed" id="33013843" target="_blank">33013843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35099507">
<a name="35099507"></a>Filippi M, Cecchetti G, Spinelli EG, Vezzulli P, Falini A, Agosta F. Amyloid-related imaging abnormalities and β-amyloid-targeting antibodies: a systematic review. <i>JAMA Neurol</i>. 2022;79(3):291-304. doi:10.1001/jamaneurol.2021.5205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lecanemab-drug-information/abstract-text/35099507/pubmed" id="35099507" target="_blank">35099507</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31827267">
<a name="31827267"></a>Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways. <i>Nat Rev Neurol</i>. 2020;16(1):30-42. doi:10.1038/s41582-019-0281-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lecanemab-drug-information/abstract-text/31827267/pubmed" id="31827267" target="_blank">31827267</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36949897">
<a name="36949897"></a>Honig LS, Barakos J, Dhadda S, et al. ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease. <i>Alzheimers Dement (N Y)</i>. 2023;9(1):e12377. doi:10.1002/trc2.12377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lecanemab-drug-information/abstract-text/36949897/pubmed" id="36949897" target="_blank">36949897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact</i>
<i>Dermatitis</i>. 2002;47(5):312-313. doi:10.1034/j.1600-0536.2002.4705104.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lecanemab-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Leqembi.1">
<a name="Leqembi.1"></a>Leqembi (lecanemab) [prescribing information]. Nutley, NJ: Eisai Inc; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lecanemab-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22235228">
<a name="22235228"></a>Palmeira P, Quinello C, Silveira-Lessa AL, Zago CA, Carneiro-Sampaio M. IgG placental transfer in healthy and pathological pregnancies. <i>Clin Dev</i>
<i>Immunol</i>. 2012;2012:985646. doi:10.1155/2012/985646<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lecanemab-drug-information/abstract-text/22235228/pubmed" id="22235228" target="_blank">22235228</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19626656">
<a name="19626656"></a>Pentsuk N, van der Laan JW. An interspecies comparison of placental antibody transfer: new insights into developmental toxicity testing of monoclonal antibodies. <i>Birth Defects Res B Dev Reprod Toxicol</i>. 2009;86(4):328-344. doi:10.1002/bdrb.20201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lecanemab-drug-information/abstract-text/19626656/pubmed" id="19626656" target="_blank">19626656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313. doi:10.1016/s0140-6736(95)90963-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lecanemab-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21784348">
<a name="21784348"></a>Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. <i>Alzheimers Dement</i>. 2011;7(4):367-385. doi:10.1016/j.jalz.2011.05.2351<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lecanemab-drug-information/abstract-text/21784348/pubmed" id="21784348" target="_blank">21784348</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36449413">
<a name="36449413"></a>Van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease.<i> N Engl J Med</i>. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/lecanemab-drug-information/abstract-text/36449413/pubmed" id="36449413" target="_blank">36449413</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 140477 Version 28.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
